September 14, 2021
OncoHelix and Canexia Health Enter Partnership to Offer Precision Oncology Genomic Testing to Canadians
OncoHelix and Canexia Health, are partnering to help Canadian cancer patients gain access to precision genomic testing via their oncologist. Using a circulating tumour DNA (ctDNA) or “liquid biopsy” blood sample, the partnership allows for Canexia Health’s Follow It® ctDNA 38-gene panel to be accessed through OncoHelix for testing services.
September 3, 2021
September 1, 2021
Personalized cancer treatment via targeted therapies is two-to-three times more effective than standard chemotherapy for patients with advanced or metastatic cancer.
August 10, 2021
Cancer patients have been heavily impacted by the ongoing COVID-19 pandemic. With thousands of tissue biopsies delayed and patients postponing clinic visits across Canada, increasing access to circulating tumour DNA (ctDNA) testing for targeted treatment selection has offered another option for oncologists.
August 4, 2021
July 20, 2021
Canexia Health recently sponsored a virtual roundtable, hosted by GenomeWeb, focused on disparities in access to precision oncology. Kellie Jack of Weill Cornell Medicine, Raymond Osarogiagbon of Baptist Cancer Center, Rachit Kumar of Maine General Medical Center, and Greg Tranah of Sutter Health discussed their perspectives working within small and large health systems across the US.